# NCT01787487 (NCT01787487)

> Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

No report yet. It can be ordered.

- Drugs tested: ruxolitinib plus azacitidine
- Indication: myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasms

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01787487
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis
- Interventions: Azacitidine; Laboratory Biomarker Analysis; Ruxolitinib Phosphate
- Enrollment: 121
- Primary outcome: Objective response rate (complete remission, partial remission, clinical improvement) in patients with myelofibrosis
- Primary outcome: Objective response rate (complete remission, partial remission, and hematologic improvement) in patients with myelodysplastic syndromes/myeloproliferative neoplasms

## Indexed commentary on NCT01787487 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 YouTube videos
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01787487